FDA expands Merck drug's approval to treat lung cancer
Advertisement
WASHINGTON: Federal health officials have expanded approval of an innovative Merck drug to treat patients with an advanced form of the most common lung cancer.
The Food and Drug Administration approved Keytruda for advanced non-small cell lung cancer patients who have not responded to other therapies. The disease accounts for roughly seven out of eight cases of lung cancer in the U.S.
Keytruda is part of a promising new class of drugs called immunotherapies, which harness the body's immune system to help fight cancer. The company's injectable biotech drug works by blocking a protein found in certain tumors called PD-1, which inhibits the body's natural response against cancer cells.
Bristol-Myers Squibb won FDA approval for a similar indication for its own PD-1 drug, Opdivo, in March.
The Food and Drug Administration approved Keytruda for advanced non-small cell lung cancer patients who have not responded to other therapies. The disease accounts for roughly seven out of eight cases of lung cancer in the U.S.
Keytruda is part of a promising new class of drugs called immunotherapies, which harness the body's immune system to help fight cancer. The company's injectable biotech drug works by blocking a protein found in certain tumors called PD-1, which inhibits the body's natural response against cancer cells.
Bristol-Myers Squibb won FDA approval for a similar indication for its own PD-1 drug, Opdivo, in March.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.